Collect Product
Product Details
Synonyms
PDCD1, PD1, CD279, SLEB2
Source
Biotinylated Human PD-1, Fc,Avitag (PD1-H82F1) is expressed from human 293 cells (HEK293). It contains AA Leu 25 - Gln 167 (Accession # Q15116-1).
Predicted N-terminus: Leu 25
Request for sequenceMolecular Characterization
Other Tags and Version Biotin & Other Labeled Version
This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).
The protein has a calculated MW of 44.4 kDa. The protein migrates as 55-66 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
Labeling
Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
Protein Ratio
Passed as determined by the HABA assay / binding ELISA.
Purity
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.
Contact us for customized product form or formulation.
Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
ACRO Quality Management System
Kunden haben auch angesehen
Data Display
SDS-PAGE
Biotinylated Human PD-1, Fc,Avitag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
SEC-MALS
The purity of Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) is more than 95% and the molecular weight of this protein is around 110-130 kDa verified by SEC-MALS.
Report
Bioactivity-ELISA
Immobilized Human PD-L1, Fc Tag (Cat. No. PD1-H5258) at 5 μg/mL (100 μL/well) can bind Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) with a linear range of 0.02-0.32 μg/mL (QC tested).
Protocol
Immobilized Nivolumab at 2 μg/mL (100 μL/well) can bind Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) with a linear range of 0.2-6 ng/mL (Routinely tested).
Protocol
Immobilized Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) at 1 μg/mL (100 μL/well) on streptavidin precoated (0.2 μg/well) plate, can bind Mouse PD-L2, His Tag (Cat. No. PD2-M52E3) with a linear range of 20-156 ng/mL (Routinely tested).
Protocol
Serial dilutions of nivolumab were added into Human PD-L1, Mouse IgG1 Fc Tag (Cat. No. PD1-H52A3): Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) binding reactions. The half maximal inhibitory concentration (IC50) is 0.3789 μg/mL (Routinely tested).
Protocol
Serial dilutions of nivolumab were added into Human PD-L2, Mouse IgG1 Fc Tag (Cat. No. PD2-H52A5): Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) binding reactions. The half maximal inhibitory concentration (IC50) is 0.2823 μg/mL (Routinely tested).
Protocol
Immobilized Cadonilimab at 1 μg/mL (100 μL/well) can bind Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) with a linear range of 0.1-4 ng/mL (Routinely tested).
Protocol
Immobilized Tebotelimab at 1 μg/mL (100 μL/well) can bind Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) with a linear range of 0.06-8 ng/mL (Routinely tested).
Protocol
Immobilized Human LAG-3, His Tag (Cat. No. LA3-H5222) at 5 μg/mL, add increasing concentrations of Tebotelimab (LAG-3 x PD-1 bispecific antibody) and then add Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) at 0.2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 26.00 ng/mL (Routinely tested).
Protocol
Immobilized Human CTLA-4, His Tag (Cat. No. CT4-H5229) at 5 μg/mL, add increasing concentrations of Cadonilimab (PD-1 x CTLA-4 bispecific antibody) and then add Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) at 0.2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 3.07 ng/mL (Routinely tested).
Protocol
Immobilized Human VEGF165, His Tag (Cat. No. VE5-H5248) at 2 μg/mL, add increasing concentrations of Ivonescimab and then add Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) at 2 μg/mL. Detection was performed using HRP-conjugated Streptavidin (Acro, Cat. No. STN-NH913) with sensitivity of 1.98 ng/mL (Routinely tested).
Protocol
Bioactivity-TR-FRET
In this TR-FRET assay, Streptavidin Protein Europium chelate (for TR-FRET) (Cat. No. FRT-TD09) is used as the Donor and Monoclonal Anti-His Tag Antibody, Rabbit IgG FA-Labeled (for TR-FRET) (Cat. No. FRT-TA11) is used as the Acceptor. Human VEGF165, His Tag (Cat. No. VE5-H5248), at 1.25 ng/well and Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1), at 1.25 ng/well, can bind to the Ivonescimab with a linear detection range of 2-0.002 μg/mL (Routinely tested).
Bioactivity-BLI
Loaded Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) on SA Biosensor, can bind Human PD-L1, His Tag (HPLC verified) (Cat. No. PD1-H5229) with an affinity constant of 2.5 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
Loaded Biotinylated Human PD-1, Fc,Avitag (Cat. No. PD1-H82F1) on SA Biosensor, can bind Human PD-L2, His Tag (SPR verified) (Cat. No. PD2-H5220) with an affinity constant of 0.31 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).
Protocol
User Reviews Publish Comment
1***22019-10-15
LikesI purchased Human PD1 and performed some QC on the antigen. HPLC and SDS PAGE experiments have been completed so far, the data was very close to what we found before. It has very good purity of SEC-HPLC and SDS-PAGE lines are very clear.- 1***22019-10-12 LikesI purchased this protein for ELISA related experiments. I coated the PD-L2 protein into the well plate, and then add antibody molecules and the biotin-PD1 to incubate. We obtained very good, stable and reproducible data.
Background Introduction
Frontier Progress
Drug Development Progress- English Name：
Programmed cell death protein 1
- Category：
- Listed Drugs Count：
22 Details
- Clinical Drugs Count：
193 Details
- Highest R&D Stage：
Approved
Contact Us
Drug Candidate Licensing
